Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

About a decade ago, at the beginning of his career in academic medicine, Brian Engelhardt, MD, MSCI, noticed that many of his patients receiving a stem cell transplant for their blood cancer ended up with diabetes.

Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can “neutralize” the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.

Patricia Griffin, MD, chief of the Enteric Diseases Epidemiology Branch at the U.S. Centers for Disease Control and Prevention (CDC), will be the guest speaker at the 2018 Vanderbilt Translational Research Forum Oc. 26 at the Vanderbilt Student Life Center.

Internationally known vaccine experts including Vanderbilt University’s James Crowe Jr., MD, will speak next month at a symposium in Nashville on prospects for a universal flu vaccine.

Researchers at Vanderbilt University Medical Center have isolated the first human monoclonal antibodies that can neutralize norovirus, the leading cause of acute gastrointestinal illness in the world.

Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.